As India works to become a biologics manufacturing hub, global life sciences leader Cytiva is expanding with the opening of a 33 000 sq ft manufacturing facility in Pune. The new facility will manufacture Cytiva’s bioprocessing equipment including tangential flow, virus filtration, and inactivation systems.

The facility will also be home to the Cytiva Experience Centre which will provide immersive training programmes for upstream and downstream technologies as well as digital and automation software. Additionally, customers will have greater access to thought leadership events and to demonstrations of Cytiva’s market-leading products, such as ÄKTA, Allegro, iCELLis and Sepax. 

Located at Hinjawadi Rajiv Gandhi Infotech Park, this new facility complements Cytiva’s existing facilities in Bengaluru which include a Fast Trak Centre, and a centre for research and development across bioprocess, discovery, medical, and genomic medicine businesses. 

According to Cytiva’s 2023 Global Biopharma Resilience Index, 65% of biopharma executives in India say that the manufacturing of biologics in their country is likely to dramatically increase over the next three years. This is 15% higher than the global average, and in line with India’s National Biopharma Mission to make India a hub for the development of novel and affordable vaccines and biologics to address the population’s health concerns.

Additionally, 46% of biopharma executives in India say that they are focusing on onshoring drug manufacturing or increasing domestic sourcing over the next 12 months to boost supply chain resilience. However, 20% of executives say that access to new equipment has become worse over the last two years, indicating a need to improve local access to equipment so that Indian companies can deliver affordable life-changing therapeutics domestically and to the region.